What does Liminatus Pharma, Inc. do?

Liminatus Pharma, Inc. is a public company in the Biological Products, (No Diagnostic Substances) industry, incorporated in DE. It is registered with the SEC under CIK 0001971387 and trades on NASDAQ under the ticker LIMNW.

Is Liminatus Pharma, Inc. profitable?

Liminatus Pharma, Inc. reported a net loss of $10.21M in FY2025. This figure is sourced from its SEC EDGAR 10-K annual report.

How many SEC filings has Liminatus Pharma, Inc. made?

Liminatus Pharma, Inc. has filed 82 documents with the SEC since 2023. These include annual reports (10-K), quarterly reports (10-Q), current event notices (8-K), and insider transaction disclosures (Form 4).

Liminatus Pharma, Inc.

LIMNW NASDAQ CIK: 0001971387 Biological Products, (No Diagnostic Substances) Inc. in DE

View on SEC.gov →

Overview All Filings Annual Quarterly Insiders

Recent Filings

All 82 filings →

Form	Description	Date
8-K	FORM 8-K	Mar 4, 2026
SCHEDULE 13G	—	Feb 20, 2026
8-K	FORM 8-K	Feb 18, 2026
424B4	424B4	Feb 18, 2026
EFFECT	—	Feb 13, 2026
S-1	S-1	Feb 11, 2026
8-K	FORM 8-K	Feb 9, 2026
8-K	FORM 8-K	Jan 26, 2026
DRS	—	Dec 31, 2025
8-K	FORM 8-K	Nov 25, 2025

Insider Transactions

View all →

No insider transactions loaded yet.

About This Profile

This page aggregates all publicly available SEC EDGAR data for Liminatus Pharma, Inc.. Financial figures are sourced from XBRL-tagged 10-K annual reports. Insider transactions are sourced from Form 4 filings required within two business days of a transaction.

Key Financials

Net Income: ($10.21M) (FY2025)
Total Assets: $512.8K (FY2025)
Operating Income: ($2.97M)

Full financials →

Details

CIK: 0001971387
Ticker: LIMNW
Exchange: NASDAQ
Incorporated: DE
First Filing: 2023
Total Filings: 82

Biological Products, (No Diagnostic Substances) rankings →